Shareholder Report | 12 Months Ended |
Aug. 31, 2024 USD ($) $ / shares |
Shareholder Report [Line Items] | | |
Document Type | N-CSR | |
Amendment Flag | false | |
Registrant Name | PUTNAM FUNDS TRUST | |
Entity Central Index Key | 0001005942 | |
Entity Investment Company Type | N-1A | |
Document Period End Date | Aug. 31, 2024 | |
Class A | | |
Shareholder Report [Line Items] | | |
Fund Name | Putnam Emerging Markets Equity Fund | |
Class Name | Class A | |
Trading Symbol | PEMMX | |
Annual or Semi-Annual Statement [Text Block] | This annual shareholder report contains important information about Putnam Emerging Markets Equity Fund for the period September 1, 2023, to August 31, 2024. | |
Shareholder Report Annual or Semi-Annual | annual shareholder report | |
Additional Information [Text Block] | You can find additional information about the Fund at https://www.franklintempleton.com/regulatory-fund-documents . You can also request this information by contacting us at (800) 225-1581 . | |
Material Fund Change Notice [Text Block] | This report describes changes to the Fund that occurred during the reporting period. | |
Additional Information Phone Number | (800) 225-1581 | |
Additional Information Website | https://www.franklintempleton.com/regulatory-fund-documents | |
Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST YEAR? (based on a hypothetical $10,000 investment) Class Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Class A $132 1.19% | [1] |
Expenses Paid, Amount | $ 132 | |
Expense Ratio, Percent | 1.19% | |
Factors Affecting Performance [Text Block] | HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE? For the twelve months ended August 31, 2024, Class A shares of Putnam Emerging Markets Equity Fund returned 22.07%. The Fund compares its performance to the MSCI Emerging Markets Index-NR, which returned 15.07% for the same period. PERFORMANCE HIGHLIGHTS Top contributors to performance: ↑ Overweight position in Intuitive Surgical, a developer of robotic-assisted surgical systems and instruments. ↑ Out-of-benchmark holding Innoviva, a diversified holding company focused on royalty generating and innovative health care assets. ↑ Overweight position in Boston Scientific, which specializes in medical technology and devices. Top detractors from performance: ↓ Overweight position in Sanofi, a multinational pharmaceutical company. ↓ Option Care Health, a provider of home infusion services. ↓ Out-of-benchmark holding TerrAscend, which specializes in medical-use cannabis. | |
Performance Past Does Not Indicate Future [Text] | The Fund’s past performance is not necessarily an indication of how the Fund will perform in the future. | |
Line Graph [Table Text Block] | | |
Average Annual Return [Table Text Block] | AVERAGE ANNUAL TOTAL RETURNS (%) Period Ended August 31, 2024 1 Year 5 Year 10 Year Class A 22.07 7.09 4.12 Class A (with sales charge) 15.05 5.83 3.51 MSCI All Country World ex-U.S. Index-NR 18.21 7.56 4.42 MSCI Emerging Markets Index-NR 15.07 4.79 2.56 | |
No Deduction of Taxes [Text Block] | The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares. | |
Updated Performance Information Location [Text Block] | For current month-end performance, please call Franklin Templeton at (800) 225-1581 or visit https://www.franklintempleton.com/investments/options/mutual-funds . Important data provider notices and terms available at www.franklintempletondatasources.com. | |
Net Assets | $ 392,366,236 | |
Holdings Count | $ / shares | 61 | [2] |
Advisory Fees Paid, Amount | $ 2,029,506 | |
Investment Company Portfolio Turnover | 55% | |
Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Total Net Assets $392,366,236 Total Number of Portfolio Holdings * 61 Total Management Fee Paid $2,029,506 Portfolio Turnover Rate 55% | [2] |
Holdings [Text Block] | | [3] |
Material Fund Change [Text Block] | HOW HAS THE FUND CHANGED? On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they had entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction (the “Transaction”). The Transaction was completed on January 1, 2024. As part of the Transaction, your Fund’s investment advisor, Putnam Investment Management, LLC (“Putnam Management”), a wholly-owned subsidiary of Putnam Holdings, and your Fund’s sub-advisors, Putnam Investments Limited (“PIL”) and The Putnam Advisory Company, LLC (“PAC”), indirect, wholly-owned subsidiaries of Putnam Holdings, became indirect, wholly-owned subsidiaries of Franklin Resources. In connection with the Transaction, shareholders of your Fund approved a new management contract with Putnam Management and new sub-advisory contracts with PIL and PAC. The new contracts are identical to the previous contracts, except for the effective dates, initial terms, updates to fund names as necessary to reflect previous name changes, and certain non-substantive changes. Effective July 15, 2024, Franklin Advisers, Inc. (“Franklin Advisers”) was retained as a sub-adviser by Putnam Management for the Fund pursuant to a new subadvisory agreement between Franklin Advisers and Putnam Management. Both Putnam Management and Franklin Advisers are wholly-owned subsidiaries of Franklin Resources. Putnam Management will continue to serve as the Fund’s investment advisor, and PIL and PAC will continue to serve as sub-advisors to the Fund. This is a summary of certain changes to the Fund since September 1, 2023. For more complete information, you may review the Fund’s current prospectus and any applicable supplements and the Fund’s next prospectus, which we expect to be available by January 1, 2025, at https://www.franklintempleton.com/regulatory-fund-documents or upon request at (800) 225-1581 or funddocuments putnam.com . | |
Updated Prospectus Phone Number | (800) 225-1581 | |
Updated Prospectus Email Address | funddocuments@putnam.com | |
Updated Prospectus Web Address | https://www.franklintempleton.com/regulatory-fund-documents | |
Class B | | |
Shareholder Report [Line Items] | | |
Fund Name | Putnam Emerging Markets Equity Fund | |
Class Name | Class B | |
Trading Symbol | PEMBX | |
Annual or Semi-Annual Statement [Text Block] | This annual shareholder report contains important information about Putnam Emerging Markets Equity Fund for the period September 1, 2023, to August 31, 2024. | |
Shareholder Report Annual or Semi-Annual | annual shareholder report | |
Additional Information [Text Block] | You can find additional information about the Fund at https://www.franklintempleton.com/regulatory-fund-documents . You can also request this information by contacting us at (800) 225-1581 . | |
Material Fund Change Notice [Text Block] | This report describes changes to the Fund that occurred during the reporting period. | |
Additional Information Phone Number | (800) 225-1581 | |
Additional Information Website | https://www.franklintempleton.com/regulatory-fund-documents | |
Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST YEAR? (based on a hypothetical $10,000 investment) Class Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Class B $214 1.94% | [4] |
Expenses Paid, Amount | $ 214 | |
Expense Ratio, Percent | 1.94% | |
Factors Affecting Performance [Text Block] | HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE? For the twelve months ended August 31, 2024, Class B shares of Putnam Emerging Markets Equity Fund returned 21.10%. The Fund compares its performance to the MSCI Emerging Markets Index-NR, which returned 15.07% for the same period. PERFORMANCE HIGHLIGHTS Top contributors to performance: ↑ Overweight position in Intuitive Surgical, a developer of robotic-assisted surgical systems and instruments. ↑ Out-of-benchmark holding Innoviva, a diversified holding company focused on royalty generating and innovative health care assets. ↑ Overweight position in Boston Scientific, which specializes in medical technology and devices. Top detractors from performance: ↓ Overweight position in Sanofi, a multinational pharmaceutical company. ↓ Option Care Health, a provider of home infusion services. ↓ Out-of-benchmark holding TerrAscend, which specializes in medical-use cannabis. | |
Performance Past Does Not Indicate Future [Text] | The Fund’s past performance is not necessarily an indication of how the Fund will perform in the future. | |
Line Graph [Table Text Block] | | |
Average Annual Return [Table Text Block] | AVERAGE ANNUAL TOTAL RETURNS (%) Period Ended August 31, 2024 1 Year 5 Year 10 Year Class B 21.10 6.29 3.51 Class B (with sales charge) 16.10 5.97 3.51 MSCI All Country World ex-U.S. Index-NR 18.21 7.56 4.42 MSCI Emerging Markets Index-NR 15.07 4.79 2.56 | |
No Deduction of Taxes [Text Block] | The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares. | |
Updated Performance Information Location [Text Block] | For current month-end performance, please call Franklin Templeton at (800) 225-1581 or visit https://www.franklintempleton.com/investments/options/mutual-funds . Important data provider notices and terms available at www.franklintempletondatasources.com. | |
Net Assets | $ 392,366,236 | |
Holdings Count | $ / shares | 61 | [5] |
Advisory Fees Paid, Amount | $ 2,029,506 | |
Investment Company Portfolio Turnover | 55% | |
Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Total Net Assets $392,366,236 Total Number of Portfolio Holdings * 61 Total Management Fee Paid $2,029,506 Portfolio Turnover Rate 55% | [5] |
Holdings [Text Block] | | [6] |
Material Fund Change [Text Block] | HOW HAS THE FUND CHANGED? On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they had entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction (the “Transaction”). The Transaction was completed on January 1, 2024. As part of the Transaction, your Fund’s investment advisor, Putnam Investment Management, LLC (“Putnam Management”), a wholly-owned subsidiary of Putnam Holdings, and your Fund’s sub-advisors, Putnam Investments Limited (“PIL”) and The Putnam Advisory Company, LLC (“PAC”), indirect, wholly-owned subsidiaries of Putnam Holdings, became indirect, wholly-owned subsidiaries of Franklin Resources. In connection with the Transaction, shareholders of your Fund approved a new management contract with Putnam Management and new sub-advisory contracts with PIL and PAC. The new contracts are identical to the previous contracts, except for the effective dates, initial terms, updates to fund names as necessary to reflect previous name changes, and certain non-substantive changes. Effective July 15, 2024, Franklin Advisers, Inc. (“Franklin Advisers”) was retained as a sub-adviser by Putnam Management for the Fund pursuant to a new subadvisory agreement between Franklin Advisers and Putnam Management. Both Putnam Management and Franklin Advisers are wholly-owned subsidiaries of Franklin Resources. Putnam Management will continue to serve as the Fund’s investment advisor, and PIL and PAC will continue to serve as sub-advisors to the Fund. Effective September 5, 2024 (the “Conversion Date”), class B shares of the Fund acquired prior to the Conversion Date converted automatically to class A shares. This is a summary of certain changes to the Fund since September 1, 2023. For more complete information, you may review the Fund’s current prospectus and any applicable supplements and the Fund’s next prospectus, which we expect to be available by January 1, 2025, at https://www.franklintempleton.com/regulatory-fund-documents or upon request at (800) 225-1581 or funddocuments putnam.com . | |
Updated Prospectus Phone Number | (800) 225-1581 | |
Updated Prospectus Email Address | funddocuments@putnam.com | |
Updated Prospectus Web Address | https://www.franklintempleton.com/regulatory-fund-documents | |
Class C | | |
Shareholder Report [Line Items] | | |
Fund Name | Putnam Emerging Markets Equity Fund | |
Class Name | Class C | |
Trading Symbol | PEMZX | |
Annual or Semi-Annual Statement [Text Block] | This annual shareholder report contains important information about Putnam Emerging Markets Equity Fund for the period September 1, 2023, to August 31, 2024. | |
Shareholder Report Annual or Semi-Annual | annual shareholder report | |
Additional Information [Text Block] | You can find additional information about the Fund at https://www.franklintempleton.com/regulatory-fund-documents . You can also request this information by contacting us at (800) 225-1581 . | |
Material Fund Change Notice [Text Block] | This report describes changes to the Fund that occurred during the reporting period. | |
Additional Information Phone Number | (800) 225-1581 | |
Additional Information Website | https://www.franklintempleton.com/regulatory-fund-documents | |
Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST YEAR? (based on a hypothetical $10,000 investment) Class Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Class C $214 1.94% | [7] |
Expenses Paid, Amount | $ 214 | |
Expense Ratio, Percent | 1.94% | |
Factors Affecting Performance [Text Block] | HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE? For the twelve months ended August 31, 2024, Class C shares of Putnam Emerging Markets Equity Fund returned 21.08%. The Fund compares its performance to the MSCI Emerging Markets Index-NR, which returned 15.07% for the same period. PERFORMANCE HIGHLIGHTS Top contributors to performance: ↑ Overweight position in Intuitive Surgical, a developer of robotic-assisted surgical systems and instruments. ↑ Out-of-benchmark holding Innoviva, a diversified holding company focused on royalty generating and innovative health care assets. ↑ Overweight position in Boston Scientific, which specializes in medical technology and devices. Top detractors from performance: ↓ Overweight position in Sanofi, a multinational pharmaceutical company. ↓ Option Care Health, a provider of home infusion services. ↓ Out-of-benchmark holding TerrAscend, which specializes in medical-use cannabis. | |
Performance Past Does Not Indicate Future [Text] | The Fund’s past performance is not necessarily an indication of how the Fund will perform in the future. | |
Line Graph [Table Text Block] | | |
Average Annual Return [Table Text Block] | AVERAGE ANNUAL TOTAL RETURNS (%) Period Ended August 31, 2024 1 Year 5 Year 10 Year Class C 21.08 6.28 3.51 Class C (with sales charge) 20.08 6.28 3.51 MSCI All Country World ex-U.S. Index-NR 18.21 7.56 4.42 MSCI Emerging Markets Index-NR 15.07 4.79 2.56 | |
No Deduction of Taxes [Text Block] | The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares. | |
Updated Performance Information Location [Text Block] | For current month-end performance, please call Franklin Templeton at (800) 225-1581 or visit https://www.franklintempleton.com/investments/options/mutual-funds . Important data provider notices and terms available at www.franklintempletondatasources.com. | |
Net Assets | $ 392,366,236 | |
Holdings Count | $ / shares | 61 | [8] |
Advisory Fees Paid, Amount | $ 2,029,506 | |
Investment Company Portfolio Turnover | 55% | |
Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Total Net Assets $392,366,236 Total Number of Portfolio Holdings * 61 Total Management Fee Paid $2,029,506 Portfolio Turnover Rate 55% | [8] |
Holdings [Text Block] | | [9] |
Material Fund Change [Text Block] | HOW HAS THE FUND CHANGED? On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they had entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction (the “Transaction”). The Transaction was completed on January 1, 2024. As part of the Transaction, your Fund’s investment advisor, Putnam Investment Management, LLC (“Putnam Management”), a wholly-owned subsidiary of Putnam Holdings, and your Fund’s sub-advisors, Putnam Investments Limited (“PIL”) and The Putnam Advisory Company, LLC (“PAC”), indirect, wholly-owned subsidiaries of Putnam Holdings, became indirect, wholly-owned subsidiaries of Franklin Resources. In connection with the Transaction, shareholders of your Fund approved a new management contract with Putnam Management and new sub-advisory contracts with PIL and PAC. The new contracts are identical to the previous contracts, except for the effective dates, initial terms, updates to fund names as necessary to reflect previous name changes, and certain non-substantive changes. Effective July 15, 2024, Franklin Advisers, Inc. (“Franklin Advisers”) was retained as a sub-adviser by Putnam Management for the Fund pursuant to a new subadvisory agreement between Franklin Advisers and Putnam Management. Both Putnam Management and Franklin Advisers are wholly-owned subsidiaries of Franklin Resources. Putnam Management will continue to serve as the Fund’s investment advisor, and PIL and PAC will continue to serve as sub-advisors to the Fund. This is a summary of certain changes to the Fund since September 1, 2023. For more complete information, you may review the Fund’s current prospectus and any applicable supplements and the Fund’s next prospectus, which we expect to be available by January 1, 2025, at https://www.franklintempleton.com/regulatory-fund-documents or upon request at (800) 225-1581 or funddocuments putnam.com . | |
Updated Prospectus Phone Number | (800) 225-1581 | |
Updated Prospectus Email Address | funddocuments@putnam.com | |
Updated Prospectus Web Address | https://www.franklintempleton.com/regulatory-fund-documents | |
Class R | | |
Shareholder Report [Line Items] | | |
Fund Name | Putnam Emerging Markets Equity Fund | |
Class Name | Class R | |
Trading Symbol | PEMLX | |
Annual or Semi-Annual Statement [Text Block] | This annual shareholder report contains important information about Putnam Emerging Markets Equity Fund for the period September 1, 2023, to August 31, 2024. | |
Shareholder Report Annual or Semi-Annual | annual shareholder report | |
Additional Information [Text Block] | You can find additional information about the Fund at https://www.franklintempleton.com/regulatory-fund-documents . You can also request this information by contacting us at (800) 225-1581 . | |
Material Fund Change Notice [Text Block] | This report describes changes to the Fund that occurred during the reporting period. | |
Additional Information Phone Number | (800) 225-1581 | |
Additional Information Website | https://www.franklintempleton.com/regulatory-fund-documents | |
Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST YEAR? (based on a hypothetical $10,000 investment) Class Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Class R $160 1.44% | [10] |
Expenses Paid, Amount | $ 160 | |
Expense Ratio, Percent | 1.44% | |
Factors Affecting Performance [Text Block] | HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE? For the twelve months ended August 31, 2024, Class R shares of Putnam Emerging Markets Equity Fund returned 21.65%. The Fund compares its performance to the MSCI Emerging Markets Index-NR, which returned 15.07% for the same period. PERFORMANCE HIGHLIGHTS Top contributors to performance: ↑ Overweight position in Intuitive Surgical, a developer of robotic-assisted surgical systems and instruments. ↑ Out-of-benchmark holding Innoviva, a diversified holding company focused on royalty generating and innovative health care assets. ↑ Overweight position in Boston Scientific, which specializes in medical technology and devices. Top detractors from performance: ↓ Overweight position in Sanofi, a multinational pharmaceutical company. ↓ Option Care Health, a provider of home infusion services. ↓ Out-of-benchmark holding TerrAscend, which specializes in medical-use cannabis. | |
Performance Past Does Not Indicate Future [Text] | The Fund’s past performance is not necessarily an indication of how the Fund will perform in the future. | |
Line Graph [Table Text Block] | | |
Average Annual Return [Table Text Block] | AVERAGE ANNUAL TOTAL RETURNS (%) Period Ended August 31, 2024 1 Year 5 Year 10 Year Class R 21.65 6.80 3.87 MSCI All Country World ex-U.S. Index-NR 18.21 7.56 4.42 MSCI Emerging Markets Index-NR 15.07 4.79 2.56 | |
No Deduction of Taxes [Text Block] | The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares. | |
Updated Performance Information Location [Text Block] | For current month-end performance, please call Franklin Templeton at (800) 225-1581 or visit https://www.franklintempleton.com/investments/options/mutual-funds . Important data provider notices and terms available at www.franklintempletondatasources.com. | |
Net Assets | $ 392,366,236 | |
Holdings Count | $ / shares | 61 | [11] |
Advisory Fees Paid, Amount | $ 2,029,506 | |
Investment Company Portfolio Turnover | 55% | |
Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Total Net Assets $392,366,236 Total Number of Portfolio Holdings * 61 Total Management Fee Paid $2,029,506 Portfolio Turnover Rate 55% | [11] |
Holdings [Text Block] | | [12] |
Material Fund Change [Text Block] | HOW HAS THE FUND CHANGED? On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they had entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction (the “Transaction”). The Transaction was completed on January 1, 2024. As part of the Transaction, your Fund’s investment advisor, Putnam Investment Management, LLC (“Putnam Management”), a wholly-owned subsidiary of Putnam Holdings, and your Fund’s sub-advisors, Putnam Investments Limited (“PIL”) and The Putnam Advisory Company, LLC (“PAC”), indirect, wholly-owned subsidiaries of Putnam Holdings, became indirect, wholly-owned subsidiaries of Franklin Resources. In connection with the Transaction, shareholders of your Fund approved a new management contract with Putnam Management and new sub-advisory contracts with PIL and PAC. The new contracts are identical to the previous contracts, except for the effective dates, initial terms, updates to fund names as necessary to reflect previous name changes, and certain non-substantive changes. Effective July 15, 2024, Franklin Advisers, Inc. (“Franklin Advisers”) was retained as a sub-adviser by Putnam Management for the Fund pursuant to a new subadvisory agreement between Franklin Advisers and Putnam Management. Both Putnam Management and Franklin Advisers are wholly-owned subsidiaries of Franklin Resources. Putnam Management will continue to serve as the Fund’s investment advisor, and PIL and PAC will continue to serve as sub-advisors to the Fund. This is a summary of certain changes to the Fund since September 1, 2023. For more complete information, you may review the Fund’s current prospectus and any applicable supplements and the Fund’s next prospectus, which we expect to be available by January 1, 2025, at https://www.franklintempleton.com/regulatory-fund-documents or upon request at (800) 225-1581 or funddocuments putnam.com . | |
Updated Prospectus Phone Number | (800) 225-1581 | |
Updated Prospectus Email Address | funddocuments@putnam.com | |
Updated Prospectus Web Address | https://www.franklintempleton.com/regulatory-fund-documents | |
Class R6 | | |
Shareholder Report [Line Items] | | |
Fund Name | Putnam Emerging Markets Equity Fund | |
Class Name | Class R6 | |
Trading Symbol | PEMQX | |
Annual or Semi-Annual Statement [Text Block] | This annual shareholder report contains important information about Putnam Emerging Markets Equity Fund for the period September 1, 2023, to August 31, 2024. | |
Shareholder Report Annual or Semi-Annual | annual shareholder report | |
Additional Information [Text Block] | You can find additional information about the Fund at https://www.franklintempleton.com/regulatory-fund-documents . You can also request this information by contacting us at (800) 225-1581 . | |
Material Fund Change Notice [Text Block] | This report describes changes to the Fund that occurred during the reporting period. | |
Additional Information Phone Number | (800) 225-1581 | |
Additional Information Website | https://www.franklintempleton.com/regulatory-fund-documents | |
Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST YEAR? (based on a hypothetical $10,000 investment) Class Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Class R6 $85 0.76% | [13] |
Expenses Paid, Amount | $ 85 | |
Expense Ratio, Percent | 0.76% | |
Factors Affecting Performance [Text Block] | HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE? For the twelve months ended August 31, 2024, Class R6 shares of Putnam Emerging Markets Equity Fund returned 22.53%. The Fund compares its performance to the MSCI Emerging Markets Index-NR, which returned 15.07% for the same period. PERFORMANCE HIGHLIGHTS Top contributors to performance: ↑ Overweight position in Intuitive Surgical, a developer of robotic-assisted surgical systems and instruments. ↑ Out-of-benchmark holding Innoviva, a diversified holding company focused on royalty generating and innovative health care assets. ↑ Overweight position in Boston Scientific, which specializes in medical technology and devices. Top detractors from performance: ↓ Overweight position in Sanofi, a multinational pharmaceutical company. ↓ Option Care Health, a provider of home infusion services. ↓ Out-of-benchmark holding TerrAscend, which specializes in medical-use cannabis. | |
Performance Past Does Not Indicate Future [Text] | The Fund’s past performance is not necessarily an indication of how the Fund will perform in the future. | |
Line Graph [Table Text Block] | | |
Average Annual Return [Table Text Block] | AVERAGE ANNUAL TOTAL RETURNS (%) Period Ended August 31, 2024 1 Year 5 Year 10 Year Class R6 22.53 7.54 4.51 MSCI All Country World ex-U.S. Index-NR 18.21 7.56 4.42 MSCI Emerging Markets Index-NR 15.07 4.79 2.56 | |
No Deduction of Taxes [Text Block] | The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares. | |
Updated Performance Information Location [Text Block] | For current month-end performance, please call Franklin Templeton at (800) 225-1581 or visit https://www.franklintempleton.com/investments/options/mutual-funds . Important data provider notices and terms available at www.franklintempletondatasources.com. | |
Net Assets | $ 392,366,236 | |
Holdings Count | $ / shares | 61 | [14] |
Advisory Fees Paid, Amount | $ 2,029,506 | |
Investment Company Portfolio Turnover | 55% | |
Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Total Net Assets $392,366,236 Total Number of Portfolio Holdings * 61 Total Management Fee Paid $2,029,506 Portfolio Turnover Rate 55% | [14] |
Holdings [Text Block] | | [15] |
Material Fund Change [Text Block] | HOW HAS THE FUND CHANGED? On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they had entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction (the “Transaction”). The Transaction was completed on January 1, 2024. As part of the Transaction, your Fund’s investment advisor, Putnam Investment Management, LLC (“Putnam Management”), a wholly-owned subsidiary of Putnam Holdings, and your Fund’s sub-advisors, Putnam Investments Limited (“PIL”) and The Putnam Advisory Company, LLC (“PAC”), indirect, wholly-owned subsidiaries of Putnam Holdings, became indirect, wholly-owned subsidiaries of Franklin Resources. In connection with the Transaction, shareholders of your Fund approved a new management contract with Putnam Management and new sub-advisory contracts with PIL and PAC. The new contracts are identical to the previous contracts, except for the effective dates, initial terms, updates to fund names as necessary to reflect previous name changes, and certain non-substantive changes. Effective July 15, 2024, Franklin Advisers, Inc. (“Franklin Advisers”) was retained as a sub-adviser by Putnam Management for the Fund pursuant to a new subadvisory agreement between Franklin Advisers and Putnam Management. Both Putnam Management and Franklin Advisers are wholly-owned subsidiaries of Franklin Resources. Putnam Management will continue to serve as the Fund’s investment advisor, and PIL and PAC will continue to serve as sub-advisors to the Fund. This is a summary of certain changes to the Fund since September 1, 2023. For more complete information, you may review the Fund’s current prospectus and any applicable supplements and the Fund’s next prospectus, which we expect to be available by January 1, 2025, at https://www.franklintempleton.com/regulatory-fund-documents or upon request at (800) 225-1581 or funddocuments putnam.com . | |
Updated Prospectus Phone Number | (800) 225-1581 | |
Updated Prospectus Email Address | funddocuments@putnam.com | |
Updated Prospectus Web Address | https://www.franklintempleton.com/regulatory-fund-documents | |
Class Y | | |
Shareholder Report [Line Items] | | |
Fund Name | Putnam Emerging Markets Equity Fund | |
Class Name | Class Y | |
Trading Symbol | PEMYX | |
Annual or Semi-Annual Statement [Text Block] | This annual shareholder report contains important information about Putnam Emerging Markets Equity Fund for the period September 1, 2023, to August 31, 2024. | |
Shareholder Report Annual or Semi-Annual | annual shareholder report | |
Additional Information [Text Block] | You can find additional information about the Fund at https://www.franklintempleton.com/regulatory-fund-documents . You can also request this information by contacting us at (800) 225-1581 . | |
Material Fund Change Notice [Text Block] | This report describes changes to the Fund that occurred during the reporting period. | |
Additional Information Phone Number | (800) 225-1581 | |
Additional Information Website | https://www.franklintempleton.com/regulatory-fund-documents | |
Expenses [Text Block] | WHAT WERE THE FUND COSTS FOR THE LAST YEAR? (based on a hypothetical $10,000 investment) Class Name Costs of a $10,000 investment Costs paid as a percentage of a $10,000 investment * Class Y $104 0.94% | [16] |
Expenses Paid, Amount | $ 104 | |
Expense Ratio, Percent | 0.94% | |
Factors Affecting Performance [Text Block] | HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE? For the twelve months ended August 31, 2024, Class Y shares of Putnam Emerging Markets Equity Fund returned 22.22%. The Fund compares its performance to the MSCI Emerging Markets Index-NR, which returned 15.07% for the same period. PERFORMANCE HIGHLIGHTS Top contributors to performance: ↑ Overweight position in Intuitive Surgical, a developer of robotic-assisted surgical systems and instruments. ↑ Out-of-benchmark holding Innoviva, a diversified holding company focused on royalty generating and innovative health care assets. ↑ Overweight position in Boston Scientific, which specializes in medical technology and devices. Top detractors from performance: ↓ Overweight position in Sanofi, a multinational pharmaceutical company. ↓ Option Care Health, a provider of home infusion services. ↓ Out-of-benchmark holding TerrAscend, which specializes in medical-use cannabis. | |
Performance Past Does Not Indicate Future [Text] | The Fund’s past performance is not necessarily an indication of how the Fund will perform in the future. | |
Line Graph [Table Text Block] | | |
Average Annual Return [Table Text Block] | AVERAGE ANNUAL TOTAL RETURNS (%) Period Ended August 31, 2024 1 Year 5 Year 10 Year Class Y 22.22 7.35 4.39 MSCI All Country World ex-U.S. Index-NR 18.21 7.56 4.42 MSCI Emerging Markets Index-NR 15.07 4.79 2.56 | |
No Deduction of Taxes [Text Block] | The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares. | |
Updated Performance Information Location [Text Block] | For current month-end performance, please call Franklin Templeton at (800) 225-1581 or visit https://www.franklintempleton.com/investments/options/mutual-funds . Important data provider notices and terms available at www.franklintempletondatasources.com. | |
Net Assets | $ 392,366,236 | |
Holdings Count | $ / shares | 61 | [17] |
Advisory Fees Paid, Amount | $ 2,029,506 | |
Investment Company Portfolio Turnover | 55% | |
Additional Fund Statistics [Text Block] | KEY FUND STATISTICS (as of August 31, 2024) Total Net Assets $392,366,236 Total Number of Portfolio Holdings * 61 Total Management Fee Paid $2,029,506 Portfolio Turnover Rate 55% | [17] |
Holdings [Text Block] | | [18] |
Material Fund Change [Text Block] | HOW HAS THE FUND CHANGED? On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they had entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction (the “Transaction”). The Transaction was completed on January 1, 2024. As part of the Transaction, your Fund’s investment advisor, Putnam Investment Management, LLC (“Putnam Management”), a wholly-owned subsidiary of Putnam Holdings, and your Fund’s sub-advisors, Putnam Investments Limited (“PIL”) and The Putnam Advisory Company, LLC (“PAC”), indirect, wholly-owned subsidiaries of Putnam Holdings, became indirect, wholly-owned subsidiaries of Franklin Resources. In connection with the Transaction, shareholders of your Fund approved a new management contract with Putnam Management and new sub-advisory contracts with PIL and PAC. The new contracts are identical to the previous contracts, except for the effective dates, initial terms, updates to fund names as necessary to reflect previous name changes, and certain non-substantive changes. Effective July 15, 2024, Franklin Advisers, Inc. (“Franklin Advisers”) was retained as a sub-adviser by Putnam Management for the Fund pursuant to a new subadvisory agreement between Franklin Advisers and Putnam Management. Both Putnam Management and Franklin Advisers are wholly-owned subsidiaries of Franklin Resources. Putnam Management will continue to serve as the Fund’s investment advisor, and PIL and PAC will continue to serve as sub-advisors to the Fund. This is a summary of certain changes to the Fund since September 1, 2023. For more complete information, you may review the Fund’s current prospectus and any applicable supplements and the Fund’s next prospectus, which we expect to be available by January 1, 2025, at https://www.franklintempleton.com/regulatory-fund-documents or upon request at (800) 225-1581 or funddocuments putnam.com . | |
Updated Prospectus Phone Number | (800) 225-1581 | |
Updated Prospectus Email Address | funddocuments@putnam.com | |
Updated Prospectus Web Address | https://www.franklintempleton.com/regulatory-fund-documents | |
|
[1] * Reflects fee waivers and/or expense reimbursements, without which expenses would have been higher. * Includes derivatives, if applicable. Cash and Equivalents, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Holdings and allocations may vary over time. * Reflects fee waivers and/or expense reimbursements, without which expenses would have been higher. * Includes derivatives, if applicable. Cash and Equivalents, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Holdings and allocations may vary over time. * Reflects fee waivers and/or expense reimbursements, without which expenses would have been higher. * Includes derivatives, if applicable. Cash and Equivalents, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Holdings and allocations may vary over time. * Reflects fee waivers and/or expense reimbursements, without which expenses would have been higher. * Includes derivatives, if applicable. Cash and Equivalents, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Holdings and allocations may vary over time. * Reflects fee waivers and/or expense reimbursements, without which expenses would have been higher. * Includes derivatives, if applicable. Cash and Equivalents, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Holdings and allocations may vary over time. * Reflects fee waivers and/or expense reimbursements, without which expenses would have been higher. * Includes derivatives, if applicable. Cash and Equivalents, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Holdings and allocations may vary over time. |